Peptide Encyclopedia / Orforglipron
EncyclopediaOrforglipron is an oral small-molecule GLP-1 receptor agonist from Eli Lilly that raises satiety, cuts food intake, and improves glycemic control without the food and water timing rules of peptide GLP-1 pills. The FDA approved it in April 2026 as Foundayo for chronic weight management. Educational only, not medical advice.
| Category | GLP-1 / Metabolic |
| Regulatory status | FDA-approved (April 2026) under the brand name Foundayo (Eli Lilly) for chronic weight management in adults with obesity or overweight with weight-related comorbidities. |
An oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly; it activates the GLP-1 receptor to increase satiety, reduce food intake, and improve glycemic control. Because it is a small molecule it can be taken orally without the food/water timing restrictions of peptide oral GLP-1s.
Long enough to support once-daily oral dosing (reported roughly in the range of a day); exact published human value varies. It is a small molecule, not a peptide.
FDA-approved (April 2026) under the brand name Foundayo (Eli Lilly) for chronic weight management in adults with obesity or overweight with weight-related comorbidities. As of mid-2026 it is marketed as an oral GLP-1 weight-loss pill without food/water timing restrictions.
Class-typical gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, decreased appetite). Refer to the approved label for contraindications and warnings.
Multiple Phase 3 human trials (basis for FDA approval).
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Orforglipron may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
